AU-12122
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
CDK
Description:
AU-12122 is a novel-developed CDK7 inhibitor, which is potent and orally bioactive. It induces apoptosis of acute monocytic leukemia THP-1.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
CDK7 inhibitor, acute monocytic leukemia
MSDS:
Inquire
Application:
the potential treatment of acute monocytic leukemia
Current Developer:
Aurigene
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


Ca2+ Channel Agonist 1
(CAS: 1402821-24-2)

A Ca2+ Channel Agonist that selectively acting on N-type Ca2+ channel and also be found to restrain the cdk activity at some extent. IC50: 14.23 uM (EC50, Ca2+ ...

CAS 142273-20-9 Kenpaullone

Kenpaullone
(CAS: 142273-20-9)

Kenpaullone is a potent inhibitor of CDK1/cyclin B (IC50 = 400 nM), CDK2/cyclin A (IC50 = 680 nM), CDK2/cyclin E (IC50 = 7.5 uM) and CDK5/p25 (IC50 = 850 nM). K...

CAS 1619903-54-6 LY2857785

LY2857785
(CAS: 1619903-54-6)

LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result i...

CAS 902135-91-5 AT7519 HCl

AT7519 HCl
(CAS: 902135-91-5)

THZ1-R
(CAS: 1621523-07-6)

THZ1-R, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor but has instability in vivo.

CAS 1073485-20-7 LDC000067

LDC000067
(CAS: 1073485-20-7)

LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.LDC000067 reduces Ser2-P, induces p...

CAS 1070790-89-4 CYC065

CYC065
(CAS: 1070790-89-4)

CYC065 is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with potential antineoplastic and chemoprotective activities.

CAS 784210-87-3 RGB-286638

RGB-286638
(CAS: 784210-87-3)

RGB-286638 is a novel CDK inhibitor. It inhibited several tyrosine and serine/threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1. It demonstrated eq...

CAS 496864-16-5 Aloisine A

Aloisine A
(CAS: 496864-16-5)

Aloisine a is a cell-permeable pyrrolo-pyrazine compound that acts as a potent, selective, reversible, and ATP-competitive inhibitor of cyclin dependent kinases...

CDK9-IN-6
(CAS: 1391855-95-0)

CDK9-IN-6, one of the CDK9 inhibitors, probably have potential activity in influencing cell cycle of T-type cells.

CAS 571190-30-2 PD 0332991

PD 0332991
(CAS: 571190-30-2)

CAS 1414943-88-6 BAY-1143572

BAY-1143572
(CAS: 1414943-88-6)

BAY 1143572 is a highly selective, potent and orally available inhibitor ofPTEFb/CDK9 and shows convincing anti-tumor activity in multiple xenograft models by t...

CAS 131740-09-5 Flavopiridol Hydrochloride

Flavopiridol Hydrochloride
(CAS: 131740-09-5)

Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/...

CAS 1231930-82-7 abemaciclib mesylate

abemaciclib mesylate
(CAS: 1231930-82-7)

Abemaciclib mesylate is a CDK inhiibitor with selectivity for CDK4 and CDK6. It was approved for the treatment of advanced or metastatic breast cancers.

CAS 1269815-17-9 CDK-IN-2

CDK-IN-2
(CAS: 1269815-17-9)

CDK-IN-2 is a potent and sepecific CDK inhibitor.

THZ2
(CAS: 1604810-84-5)

THZ2, an analog of THZ1, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor which overcomes the insta...

CAS 827022-32-2 Palbociclib HCl

Palbociclib HCl
(CAS: 827022-32-2)

Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic acti...

CAS 582315-72-8 BMS-265246

BMS-265246
(CAS: 582315-72-8)

BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM. It is 25-fold more selective for CDK1/2 than CDK4.

CAS 1883423-59-3 MSC2530818

MSC2530818
(CAS: 1883423-59-3)

MSC2530818 is a specific and orally available CDK8 Inhibitor with an IC50 of 2.6 nM for CDK8.

CAS 1204918-72-8 SB1317

SB1317
(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

Quick Inquiry

Verification code

Featured Items